Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 20;15:27. doi: 10.1186/s13148-023-01441-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Gene expression of BCL2 and PLC genes in MDS patients. A BCL2 gene expression in cells obtained from MDS patients at baseline (T0), after 4 (T4) and 8 (T8) cycles of AZA + LEN therapy. Responder patients (R) show high levels of BCL2 at T0, T4 and T8, as compared to healthy subjects (HD), increasing levels at T4 (vs T0) and a reduction at T8 (vs T4). Patients losing response (LR) show high levels at T0 (statistically significant), T4 and T8 as compared to healthy subjects (HD), a constant amount at T4 (vs T0) and a slight reduction at T8 (vs T4). Non-responder (NR) patients show high levels of BCL2 at T0, T4 and T8, whose difference with healthy subjects (HD) is always statistically significant. During treatment, the amount of BCL2 in NR is slightly reduced. B PLCB1 expression in MDS patients at baseline (T0), after 4 (T4) and 8 (T8) cycles of AZA + LEN therapy. All patients’ subgroups [responders (R), losing response (LR), and non-responders (NR)] show higher levels of PLCB1, that are not statistically different from healthy subjects (HD). At T4, all patients’ subgroups show a slight induction (as compared with T0) and a subsequent reduction at T8 (vs T4), with LR and NR subgroups always showing higher levels than R. C PLCG1 expression in MDS patients at baseline (T0), after 4 (T4) and 8 (T8) cycles of AZA + LEN therapy. All patients’ subgroups [responders (R), losing response (LR), and non-responders (NR)] show higher levels of PLCG1, that are not statistically different from healthy subjects (HD). At T4, LR and NR subgroups show a reduction, while R display a slight increase, as compared with T0 (not statistically significant). At T8, R and NR show a reduction and LR display a slight increase, as compared with T4 (not statistically significant). All data are represented as mean ± SD. Each experiment was repeated at least three times, with at least six replicates for each treatment condition and patients’ subgroup. *p < 0.05 versus HD, by one-way ANOVA using Bonferroni multiple comparisons in GraphPad Prism 5